Deutetrabenazine.
As the linked article from Wikipedia notes:
Deutetrabenazine (trade name Austedo) is a vesicular monoamine
transporter 2 inhibitor which is used for the treatment of chorea
associated with Huntington's disease and tardive dyskinesia.
Chemically, deutetrabenazine is an isotopic isomer of tetrabenazine in
which six hydrogen atoms have been replaced by deuterium atoms. The
incorporation of deuterium slows the rate of drug metabolism, allowing
less frequent dosing.
Whilst what you have in the above is an isotope of hydrogen, the effect this gives is seen in other compounds belonging to the bioisosteres (chemical substituents or groups with similar physical or chemical properties which produce broadly similar biological properties in the same chemical compound), the purpose being to:
enhance the desired biological or physical properties of a compound
without making significant changes in chemical structure
The different mass of the deuterium in the case of deutetrabenzine is thought to tweak the chemistry in useful ways:
However, the C–D bond is a bit shorter, and it has reduced
electronic polarizability and less hyperconjugative stabilization of
adjacent bonds, including developing an anti-bonding orbital as part
of the newly formed bond. This can potentially result in weaker van
der Waals stabilization, and can produce other changes in properties
that are difficult to predict, including changes in the intramolecular
volume and the transition state volume